🟢 Capricor Therapeutics is trading 9% up in pre-market after FDA extends Deramiocel PDUFA date

Capricor Therapeutics is trading at $7.40 (+8.88%) after the FDA extended Deramiocel’s PDUFA date from August 22 to November 22, 2026, allowing additional time to review a BLA amendment.

• The move follows a volatile week, with shares closing at $6.80 on August 24 after several large daily swings.
• The FDA timeline remains the key catalyst, though the extension delays a regulatory decision.